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Su Jin Heo1, Se Heon Kim7, Eun Chang Choi7, Da Hee Kim7, Young Min Park7, Sangwoo Kim6, Sun Och Yoon8, Yoon Woo Koh7,
Byoung Chul Cho1 and Hye Ryun Kim1
BACKGROUND: Oropharyngeal cancer (OPC) exhibits diverse immunological properties; however, their implications for
immunotherapy are unknown.
METHODS: We analysed 37 surgically resected and nine recurrent or metastatic anti-programmed death-1 (PD-1)/programmed
death-ligand 1 (PD-L1)-treated OPC tumours. OPCs were classified into immune-rich (IR), mesenchymal (MS) and xenobiotic (XB)
subtypes based on RNA-sequencing data.
RESULTS: All IR type tumours were human papillomavirus (HPV) positive, most XB types were HPV negative, and MS types showed
mixed HPV status. The IR type showed an enriched T cell exhaustion signature with PD-1+ CD8+ T cells and type I macrophages
infiltrating the tumour nest on multiplex immunohistochemistry. The MS type showed an exclusion of CD8+ T cells from the tumour
nest and high MS and tumour growth factor-β signatures. The XB type showed scant CD8+ T cell infiltration and focal CD73
expression. The IR type was associated with a favourable response signature during anti-PD-1/PD-L1 therapy and showed a high
APOBEC mutation signature, whereas the MS and XB types showed resistance signature upregulation. Among anti-PD-1/PD-L1-
treated OPC patients, the IR type showed a favourable clinical response (3/4 patients), whereas the XB type showed early
progression (3/3 patients).
CONCLUSION: Our analysis classified OPCs into three subtypes with distinct immune microenvironments that are potentially
related to the response to anti-PD-1/PD-L1 therapy.
British Journal of Cancer (2020) 122:1649–1660; https://doi.org/10.1038/s41416-020-0796-8
BACKGROUND
Immune checkpoint blockade exerts profound anti-tumour effects
in many cancer types; however, the efficacy of immune
checkpoint blockades is greatly affected by the tumour micro-
environment. Previous studies have classified tumours into
“immune-rich” and “immune desert” types based on their
microenvironment.1 In addition, a recent study has also described
an “immune-exclusion” type that is derived from tumour growth
factor-β (TGF-β) activation with a large stromal component.2
However, the molecular determinants of the tumour immune
microenvironment are largely unknown, and numerous tumoural
and host factors, such as tumour mutational burden (TMB),3
oncogene mutations, host HLA type4 and microbiota5 are
expected to influence of the tumour microenvironment.
Recurrent and metastatic head and neck squamous cell
carcinoma (HNSCC) is incurable and causes frequent functional
disability and high mortality.6 Clinical trials have demonstrated
promising clinical efficacy of anti-programmed death-1 (PD-1)
therapy in HNSCCs, and nivolumab and pembrolizumab have been
currently approved for HNSCC refractory to platinum-based
therapy.7–9 However, the response rates of these immunotherapies
are relatively low (13‒16%), and progression-free survival is limited
in the majority of patients. Moreover, the presence of programmed
death-ligand 1 (PD-L1) on tumour cells did not satisfactorily predict
response, with 27% of PD-L1+ patients vs. 12% of PD-L1− patients
responding.8 This unsatisfactory efficacy of anti-PD-1 therapy
necessitates the development of predictive biomarkers for patient
selection and for effective combination immunotherapy.
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HNSCC arises from heterogeneous anatomical origins from the
oral cavity to the hypopharynx. Oropharyngeal cancer (OPC)
constitutes a distinct clinical subset of HNSCC with a high
prevalence of human papillomavirus (HPV)-associated
tumorigenesis.10,11 OPC tumours that are HPV positive show
superior survival outcomes and different molecular characteristics
compared with those that are HPV negative.10 Notably, HPV-
positive OPC tumours possess distinct immunological properties
relative to HPV-negative tumours and are characterised by high
levels of T lymphocyte infiltration.12 However, other studies have
also found a significant variation in the immunologic character-
istics of HPV-positive HNSCCs,13 and the response rate of HPV-
positive HNSCC tumours to anti-PD-1/PD-L1 therapy is low.8 These
results indicate that, in addition to HPV status, multiple molecular
factors affect the immunogenicity of HNSCCs. Previous genomic
studies have classified HNSCCs into different molecular
subtypes;14,15 an enhanced understanding of the immunologic
properties of each molecular subtype is predicted to contribute to
the development of effective immunotherapy for HNSCCs.
In this study, we performed a comprehensive molecular
profiling of OPC tumours and classified OPCs into three distinct
subtypes. We found a significant difference in the immune
microenvironment between the three molecular subtypes and
demonstrated a correlation between anti-PD-1/PD-L1 therapy
response and molecular subtype. These results suggest that
immune microenvironment subtyping is beneficial for the
prediction of response to immunotherapy, as well as for the
design of combination immunotherapy strategies for patients
with OPC.
METHODS
Also see Supplementary Methods for further information.
Patients
This study analysed two cohorts of patients who were diagnosed
with squamous cell carcinoma of the oropharynx by pathologic
confirmation at the Yonsei Cancer Center. The first cohort
consisted of 37 patients with local or locally advanced OPC who
received curative resection between January 2011 and December
2014. The second cohort included nine recurrent or metastatic
OPC patients who were administered anti-PD-1/PD-L1 blocking
agents between December 2016 to October 2018.
RNA-seq data analysis
Formalin-fixed and paraffin-embedded (FFPE) tumour specimens
were obtained from all patients in the two patient cohorts, and
RNA-sequencing (RNA-seq) was performed. DESeq2 package was
used for differentially expressed gene (DEG) analysis. The RNA-seq
data from OPC tumours were subjected to two-dimensional t-
distributed stochastic neighbour embedding (t-SNE) plotting
using Rtsne package. Unsupervised clustering of the t-SNE result
was performed using k-means clustering. The clustering yielded
three molecular subtypes of OPC tumours.
Targeted panel sequencing
Genomic DNA was purified from FFPE tissues and peripheral blood
mononuclear cells from patients’ blood for targeted sequencing.
As previously described,16 the 244 head and neck cancer-related
genes were incorporated into our targeted sequencing panel. To
capture the genomic regions of these genes, the customised
SureSelectXT Target Enrichment library generation kit (Agilent,
Santa Clara, CA, USA) was used.
Multiplex IHC image analysis
For multiplex immunofluorescence stain of the sections, the
automated staining system (BOND Rx, Leica Biosystems) was used
with the Opal 7-colour automation immunohistochemistry (IHC)
kit (PerkinElmer). The multi-spectral images for analyses of tissue
contents were generated from whole-slide scan images by Vectra
Polaris (PerkinElmer) and Phenochart software (PerkinElmer).
Immune cells were quantified by cell counts per mm2 in both
the tumour nest and stroma. Membranous PD-L1 or CD73
expression on tumour cells was determined by tumour proportion
score using the InForm software.
RESULTS
Molecular subtypes of surgically resected OPC tumours
We performed unsupervised clustering analysis of RNA-seq data of
37 surgically resected OPC tumours (YOPC) for molecular
subtyping. After filtering out genes with low expression, the
normalised expression values of 18,862 genes were subjected to t-
SNE analysis followed by k-means clustering. The clustering
revealed three distinct molecular subtypes of OPCs (Fig. 1a). The
subtypes were named as “immune-rich” type (IR type), “xenobio-
tic” (XB type) and “mesenchymal” (MS type), according to their
molecular nature as described later. The HPV status of tumours
was evaluated using p16 IHC analysis and validated by
HPV genotyping polymerase chain reaction (PCR). We detected
HPV DNA in 20 out of 21 (95.2%) p16-positive OPC tumours,
and HPV PCR was negative in 14 out of 16 (87.5%) p16-negative
OPC patients (Supplementary Table S1). The IR type consists of
only HPV-positive tumours, and XB type consists of mostly HPV-
negative tumours (7/8). The MS type showed mixed composition
of HPV-positive and -negative tumours. The HPV PCR and p16 IHC
results were concordant in all XB and IR type tumours. There were
two HPV PCR (+)/p16 IHC (−) tumours and one HPV PCR (−)/p16
IHC PCR (+) tumour in MS type tumours. The total smoking dose
in pack-years was higher in XB type, and MS type showed lower
tumour stage than the others (Fig. 1b and Supplementary
Tables S2 and S3). To generalise our molecular subtyping in an
independent patient cohort, we applied our subtyping to The
Cancer Genome Atlas (TCGA) HNSCC tumours with oropharyngeal
origins (n= 33). In the combined cohort of YOPC and TCGA
cohorts (total n= 70), the t-SNE and k-means clustering again
identified three molecular subtypes (Fig. 1c). The HPV-positive
tumours were similarly enriched in the IR type in TCGA cohort. The
IR and MS type patients showed significantly better overall
survival than those of XB type (Fig. 1d). We compared subtyping
results between TCGA classification and our classification in our 37
YOPC tumours (Supplementary Fig. S1a) and 33 TCGA HNSCC
tumours with oropharyngeal origins (Supplementary Fig. S1b). Our
OPC subtyping was concordant with previous TCGA classification
as follows: IR type with atypical type; XB type with classic/basal
type; and MS type with mesenchymal type. However, some cases
were discordant between our classification and TCGA classifica-
tion, because our classification is confined to OPCs, whereas TCGA
classification was derived from HNSCCs of all anatomic origins.
We identified subtype-specific gene signatures by analysing the
DEGs (Fig. 1e, Supplementary Table S4, log fold change ≥2 and
p value < 0.05) of each subtype using the RNA-seq data of
37 surgically resected OPC tumours (YOPC) and tested their
relevance in the total TCGA HNSCC cohort (n= 518). The
enrichment scores for each subtype signature in TCGA HNSCC
tumour samples were calculated by gene set variation analysis
(GSVA),17 and HNSCC tumours were classified into three subtypes
(Fig. 1f). The patients’ survival was more favourable in the order of
IR type, MS type and XB type, consistent with results from the
combined YOPC and TCGA OPC cohort. The tumour classification
using gene signature GSVA was highly concordant with t-SNE k-
means clustering analysis in both, 37 YOPC tumours (Supplemen-
tary Fig. S2a) and combined cohort tumours (37 YOPC+ 33 TCGA
tumours; Supplementary Fig. S2b).
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Characterisation of gene signatures in three OPC subtypes
To characterise the molecular properties of each subtype, the
significantly altered genes among subtypes (log fold change ≥1 and
p value < 0.05) were classified into clusters 1 to 6 (from C1 to C6) by
hierarchical clustering (Fig. 2a and Supplementary Table S5). The XB
type showed upregulation of XB metabolism genes (C1), including
AKR1C2 and AKR1C3, which participate in oxidation–reduction
processes in response to alcohol and cigarette exposure (Fig. 2b).
The IR type showed enrichment of the adaptive immune response
genes (C2), including various T cell surface markers and cell cycle-
related genes (C3) associated with HPV E6/E7 oncoprotein activity.
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contraction and cell adhesion (C4), and keratinisation (C5). Pair-wise
comparison of the interactome of the three molecular subtypes
showed activation of immunological pathways in IR type and
epithelial–mesenchymal transition (EMT) pathways in XB and MS
types (Fig. 2c). GSVA analysis using hallmark gene signatures (H) in
MSigDB also indicated significant upregulation of interferon-α/γ
(IFN-α/γ) response genes in IR type, unfolded protein response and
glycolysis genes in XB type and myogenesis genes in MS type
(Fig. 2d). The three subtypes showed differences in metabolism
gene expression signatures (red arrows in Fig. 2d), and glycolysis
signature was upregulated in XB type. We compared tumour
metabolic rate via positron emission tomography (PET) CT scan
(Fig. 2e). The XB type showed higher tumour-to-liver uptake ratio
(TLR) in 18F-fluorodeoxyglucose positron emission tomography-
computed tomography (F-18 FDG PET-CT) scan than other types,
suggesting that XB type tumours have high glycolysis activity.
Distinct immunologic properties of three subtypes
We next analysed the immunologic characteristics of OPC
subtypes at the transcriptomic level. Among immune response-
related genes (from GO term “immune response”, GO:0006955),
203 genes were significantly altered among the three subtypes
(Fig. 3a and Supplementary Table S6, log 2 fold change ≥1 and
p value < 0.05). Notably, genes related to T cell exhaustion (e.g.
PDCD1, CTLA4 and 41-BB) were selectively upregulated in IR types,
and genes related to macrophage and granulocyte infiltration and
activation (e.g. TREM1, CSF3 and CCL3) were upregulated in the XB
and MS types. Accordingly, gene set enrichment analysis (GSEA)
showed enrichment of T cell exhaustion signatures established by
previous studies (LAYN18 and Mel7519) in IR type (Fig. 3b). In
contrast, the myeloid cell- and macrophage-related signatures
were enriched in XB and MS types in comparison with the IR type.
Next, we employed the CIBERSORT algorithm20 to estimate the
composition of tumour-infiltrating immune cells (Fig. 3c). The
number of activated CD8+ T cells was significantly higher in IR
type, and that of type I macrophage was lower in the MS type.
Conversely, type II macrophage infiltration was significantly lower
in the IR type. The estimated NK cell and B cell infiltration did not
differ among the three subtypes. IR type tumours were also
predicted to be responsive to tumour immunotherapy, as
indicated by tumour immune dysfunction and exclusion (TIDE)
scores (Fig. 3d).21 These results collectively indicate IR type as
highly immunogenic and responsive to anti-PD-1/PD-L1 blockade.
Recently, Hugo et al.22 suggested the 19 gene signatures to be
innate anti-PD-1 resistance (IPRES) signatures. Of note, 18 of
19 signatures were upregulated in XB and MS type tumours
compared with those in IR type tumours (Fig. 3e). These data
support that XB and MS types may exhibit resistance to anti-PD-1/
PD-L1 therapy.
Multiplex immunohistochemistry reveals distinct immune
microenvironment of the subtypes
To directly examine the immune microenvironment of the three
OPC subtypes, we performed multiplex IHC analysis using the
Vectra imaging system in 36 of 37 OPC tumours (Fig. 4a, tumour
tissue for IHC was unavailable for one patient). The tumour-
infiltrating immune cell densities, including CD8+ T cells, PD-
1+CD8+ T cells and CD68+ macrophages were measured both in
tumour nests and stroma using automated imaging analysis.
Consistent with RNA-seq analysis, the IR type showed several PD-
1+CD8+ T cells and CD68+ type I macrophages infiltrating the
tumour nest, while the XB and MS types showed scant CD8+ T cell
infiltration in tumour nests (Fig. 4b). The density of total CD8+
T cells and PD-1+CD8+ T cells was higher in IR type tumours than
in the other types in both tumour nests and stroma (Fig. 4c). The
MS type tumours showed higher total CD8+ T cell density than XB
type, but lower tumour nest-to-stroma CD8+ T cell ratio than the
IR type, suggesting exclusion of CD8+ T cells from tumour nests
(Fig. 4d). Previous studies reported an immune-exclusion pheno-
type with enhanced TGF-β activity and high stromal component,
and the MS type tumours showed a significantly higher TGF-β-
response signature (TBRS) score2 (Fig. 4d). We also found
upregulation of CD73, which plays an important immunosuppres-
sive role in CD39/C73-dependent adenosine pathways, in tumour
cells in two XB type tumours (Fig. 4e).
Genetic alterations and TMB of subtypes
We next compared genetic alterations of OPC molecular subtypes
using targeted panel next-generation sequencing (NGS). We
performed NGS analysis of FFPE tumour samples with available
matched normal blood samples in 13 of 37 OPC patients,
including six XB type, three MS type and four IR type (Fig. 5a).
Consistent with previous reports, the XB type showed high
prevalence of p53 mutations. The non-synonymous TMB was not
different among subtypes. The non-synonymous TMB was not
different among subtypes, and there was no correlation between
TIDE score and TMB (Fig. 5b). One XB type tumour (YOPC31) had
mutations in the DNA damage pathway (RAD50, RAD51, BLM and
BRD7), with the highest mutational burden (6.24 mutations/Mb),
but the TIDE score of this tumour indicated lower responsiveness
to anti-PD-1/PD-L1 therapy. These findings are in line with a recent
report of pan-cancer database analysis, showing a discrepancy
between TMB and T cell-inflamed tumour signature.23 We also
analysed the mutation signature of tumours defined by COSMIC
database.24 The XB type showed enrichment of signature 1A (C >
T, age related), 16 (T > C, aetiology unknown) and 18 (C > A), and
MS type showed high proportion of signature 1A and 11 (C > T,
Fig. 5c). Of note, the IR type tumours were particularly enriched for
signature 2 (C > T, APOBEC related) and signature 7 (C > T,
Fig. 1 Three molecular subtypes of OPC identified by RNA-seq analysis of tumours show different survival outcomes. a The two-
dimensional t-SNE plot of RNA-seq data from 37 surgically resected OPC tumours (YOPC) with p16 IHC status. The k-means clustering analysis
classifies the tumours into three subtypes: immune-rich (IR), mesenchymal (MS) and classic (CL) type. The patient number (YOPC) corresponds to
the plots. b Comparison of smoking doses of patients among three subtypes. The smoking dose in pack-years (PYR) was compared using
Kruskal–Wallis test with post hoc analysis using Dunn’s multiple comparison test. The difference between XB and IR type OPCs was statistically
significant (p < 0.05) in the post hoc analysis and indicated with the asterisk (*p < 0.05). c The t-SNE plotting for OPC tumours of the combined
cohort, which consists of 37 OPC tumours from patients at the Yonsei Cancer Center (YOPC) and 33 HNSC TCGA tumours of oropharyngeal
origin (the soft palate, the base of tongue, the tonsils and the side and back wall of the throat). The subtype of TCGA OPC tumours was
determined by k-means clustering. d The Kaplan–Meier curves for overall survival of OPC patients in the combined cohort. The patient survival
was compared using log-rank test. The difference between XB and IR type OPCs was statistically significant (p < 0.167) after the Bonferroni post
hoc correction and indicated with the asterisk (*). e The heatmap of significantly altered genes among three subtypes (log2 fold change ≥2 and
p value < 0.05). The CL-, IR- and MS-specific gene signatures were selected according to their expression in each subtype. f The three-
dimensional plotting and k-means clustering analysis using gene set enrichment score of each subtype signature derived from e calculated by
GSVA algorithm in 518 HNSC TCGA patients (upper panel). The Kaplan–Meier curves for overall survival of 518 HNSC TCGA patients according to
subtype classification (lower panel). The difference between XB type vs. IR type OPCs was statistically significant (p < 0.167) after the Bonferroni
post hoc correction. Throughout the figures, data are mean and SEM.
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Fig. 2 Characterisation of subtype-specific gene signatures. a The differentially expressed genes among the subtypes (log fold change ≥1 and
p value < 0.05) were categorised into six clusters: xenobiotic metabolism (C1), adaptive immune response (C2), cell cycle-related (C3), smooth
muscle contraction and cell adhesion (C4), keratinisation (C5) and membrane potential regulation (C6) genes in 37 surgically resected OPC
tumours (YOPC). b Subtype-specific expression of six cluster genes. The average z-score expression of each gene is shown by a grey line, and the
average z-score expression of all genes is shown by a red line. c The network analysis of differentially expressed genes via pair-wise comparison of
each subtype using Enrichment map software in 37 YOPC tumours. d The heatmap showing enrichment score of hallmark gene signatures (H)
in MSigDB on GSVA. Red arrows indicate the gene signatures related to metabolism in 37 YOPC tumours. e Tumour-to-liver uptake ratio (TLR) from
F-18 FDG PET-CT scan of OPC tumours according to their subtype. The pre-operative PET-CT scan was available in 31 out of 37 OPC tumours, and
the representative PET/CT images of subtypes are shown. The TLR values were compared using one-way ANOVA with Bonferroni post hoc test.
The difference between XB type and MS type OPCs was statistically insignificant in the post hoc analysis. n.s., Not significant.
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Fig. 3 Distinct tumour immune microenvironment of OPC subtypes revealed by RNA-seq. a Significantly altered immune-related genes
(log2 fold change ≥1 and p value < 0.05 in GO term immune response: GO:0006955) among three subtypes. The representative genes related
to T cell adaptive immune response and macrophage/granulocyte activation are indicated. b GSEA of expression profile comparing IR type vs.
XB and MS types using T cell exhaustion (LAYN and Mel75) and myeloid cell activation (GO:0002274: myeloid leucocyte activation and
GO:0043030: regulation of macrophage activation) gene signatures. c Immune cell composition analysis using the CIBERSORT deconvolution
method. The heatmap showing the relative fraction of various types of immune cells in OPC tumours (the upper panel). The dot plot showing
ratio of CD8+ T cells, M1 macrophages and M2 macrophages in OPC tumours (the lower panels). The proportion of the cells was compared
using one-way ANOVA with Bonferroni post hoc test. The statistically significant results per post hoc analysis are indicated with asterisks (*p <
0.05). d The waterfall plot of TIDE prediction score of 37 OPC tumours. The molecular subtype is indicated by a different colour. A low TIDE
score means a high probability of response to immune checkpoint blockade therapy. e The heatmap of the gene set enrichment score of 19
IPRES gene sets calculated by GSVA in 37 OPC patients.
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Fig. 4 Distinct immune microenvironment of OPC subtypes revealed by multiplex IHC. a The representative multiplex IHC image of OPC
tumour. The representative tumour nest and stroma sites were selected, and the density of CD8+ T cells and CD68+ macrophages, as well as
the proportion of CD73+ tumour cells were counted both in tumour nests and stroma. b The representative multiplex IHC images of subtypes
of OPC tumours. c The dot plots of immune cell densities of OPC tumours, total CD8+ T cells, PD-1+CD8+ T cells and CD68+ macrophages
both in tumour nests and stroma. d The ratio of CD8+ T cell density in tumour nest to CD8+ T cell density in stroma in the three subtypes (left
panel). The f-TBRS score of the three subtypes in 37 YOPC tumours (right panel). e The representative CD73 IHC image of two XB type tumours
(YOPC8 and YOPC32, upper panel). The dot plot of the proportion of CD73+ tumour cells in the subtypes (lower panel). The cell densities (c)
and f-TBRS (d) were compared using one-way ANOVA with Bonferroni post hoc test. The statistically significant results per post hoc analysis
are indicated with asterisks (*p < 0.05).
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Fig. 5 Analysis of subtype-specific genetic properties by next-generation sequencing of OPC tumour DNA. a The oncomap showing
genetic alterations of OPC tumours. The tumour-blood-matched targeted panel sequencing was performed in 13 out 37 OPC patients with
available samples. The tumour subtype is indicated at the bottom of the map and the tumour mutation burden (TMB, non-synonymous
mutations/Mb) was plotted. b The plot showing correlation between tumour mutation burden and TIDE score in OPC tumours. c Pie charts
showing the proportion of COSMIC mutational signatures in XB type, MS type and IR type of OPC tumours. b The dot plot comparing the
expression level of APOBEC family genes, APOBEC3B, APOBEC3D and APOBEC3G, in the three subtypes. The normalised expression level on
RNA-seq was compared by unpaired t test. The expression values were compared using one-way ANOVA with Bonferroni post hoc test. The
statistically significant results per post hoc analysis are indicated with asterisks (*p < 0.05).
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ultraviolet light related). Accordingly, we found upregulation of
APOBEC family genes (APOBEC3B, APOBEC3D and APOBECC3G) in
IR type tumours compared with that in other types (Fig. 5d). These
results suggest that IR type tumours show a distinct genetic
aetiology of APOBEC activation, in accordance with previous
studies reporting correlation of HPV-positive tumours with
APOBEC mutation signatures and high immunogenicity of
tumours with APOBEC mutation signatures.25
Immune microenvironment subtype predicts response to
anti-PD-1/PD-L1 therapy
We evaluated the predictive utility of the present OPC subtype
classification in the response to anti-PD-1/PD-L1 therapy in OPC
patients. We analysed pre-treatment tumour samples from nine
patients with metastatic or recurrent OPC receiving anti-PD-1/PD-
L1 therapy (YOPD, Fig. 6a). Employing t-SNE plotting combined
with 37 surgically resected OPC tumours, we classified the nine
YOPD tumours into four IR type, two MS type and three XB type
tumours (Fig. 6b). Demonstrating the clinical significance of our
subtyping, 75% of IR type tumours (3/4) showed tumour shrinkage
(1/4) or tumour control (2/4) for more than 4 months upon anti-
PD-1/PD-L1 therapy, whereas no XB type tumour showed clinical
benefit from the anti-PD-1/PD-L1 therapy (Fig. 6c, d). Of the two
MS type tumours, one showed a clinical benefit from anti-PD-1/
PD-L1 therapy and the other did not. Although clinical significance
of anecdotal findings stated above is limited by small sample size,
these results suggest the potential poor response of XB type and
favourable response of IR type OPCs to anti-PD-1/PD-L1 therapy.
DISCUSSION
The tumour microenvironment is based on competitive and
cooperative interaction between tumour cells and tumour-
infiltrating immune cells. Tumour cells evade immune responses
by suppressing T lymphocyte functions and activating immune-
suppressive cells. These immunologic dynamics influence the
growth and metastasis of malignant tumours, as well as response
to tumour immunotherapy. Here, we proposed molecular subtyp-
ing of OPCs to link the molecular aetiologies of tumours to their
immune microenvironment properties. The three OPC subtypes, IR
type, MS type and XB type, are related to adaptive immune
response, MS response signatures and XB response signatures,
respectively. Our analysis revealed distinct immunological profiles
of each subtype that can be translated to diagnosis and treatment
of OPC patients. We suggest that IR type tumours are strong
responders to anti-PD-1/PD-L1 therapy with high immunogenicity,
and the combination of anti-TGF-β therapy with immunotherapy
would be useful for treating the MS type. The XB type exhibits
potent innate resistance to anti-PD-1/PD-L1 therapy, and anti-
CD73 treatment may provide therapeutic benefits in this subtype.
T cell-inflamed tumours show favourable survival outcomes in
many cancer types,26–28 and a previous study showed a higher
CD8+ T cell density in HPV-positive HNSCC tumours than in HPV-
negative tumours.12 Moreover, evasion of the immune response
against foreign HPV viral antigens in tumour cells is dependent on
the PD-1/PD-L1 axis, suggesting that HPV-positive tumours are
susceptible to the immune checkpoint pathway.29 Accordingly,
the high T cell gene signature with positive HPV status of IR type
tumours may explain the favourable prognosis and high respon-
siveness to anti-PD-1/PD-L1 therapy. However, it should also be
noted that not all HPV-positive tumours were IR type, and a subset
of HPV-positive tumours was classified as MS or XB type in our
study. Previous studies indicated that HPV-positive HNSCC also
involves downregulation of antigen-processing machineries,30
increased Treg infiltration31 and high IDO1 expression,32 suggest-
ing that HPV-positive tumours are also dependent on various
immune evasion mechanisms. Moreover, previous clinical trials
demonstrated little difference in efficacy of anti-PD-1/PD-L1
therapy between HPV-positive and -negative HNSCCs.7,8 Our
study implies that the immune response of OPC tumours is not
determined solely by HPV status, as the immune microenviron-
ment affects the anti-tumour immune response of OPC tumours.
In this study, a considerable proportion of tumours were
classified as “MS” with high TGF-β activity. As demonstrated by a
recent study, TGF-β signalling acts as the central node in the
immune-exclusion phenotype, in which a high stromal compo-
nent excludes T cells from tumour nests in bladder cancer
models.2 We found a similar immune-exclusion mechanism in the
MS type OPC tumours, as indicated by concomitant T cell
exclusion and upregulation of f-TBRS. We expect that TGF-β
signal inhibitors would be particularly beneficial in MS subtypes
when combined with immune checkpoint blockade in clinical
settings.
Results for targeted panel sequencing showed that the TMB
was not significantly different among subtypes and that the TMB
did not correlate with T cell infiltration signature. High TMB and T
cell inflammation signature have been regarded as essential
predictive biomarkers in immune checkpoint blockade therapy;
however, a recent study revealed that these two markers have
low correlation.23 Based on the present data, it is not clear
whether high TMB XB type tumours are susceptible to anti-PD-1/
PD-L1 therapy. However, our data suggest that immune-
suppressive mechanisms, including the adenosine pathway with
CD39/CD73 expression, may be active in XB type tumours. Our
genomics analysis also revealed high APOBEC mutation signature
in IR type tumours. A previous study pointed out that strong
response to immunotherapy in non-small-cell lung cancer
patients is related to high APOBEC signatures,25 and another
reported high PD-1 expression in hypermutated bladder cancer
tumours with APOBEC signatures.33 Therefore, the high immu-
nogenicity of the IR type may be related to the high APOBEC
activity in the tumour cells. Our results collectively suggest that
the different immunologic properties of OPC subtypes originate
from their different genetic aetiologies.
Although immune checkpoint blockades elicit long-term clinical
benefit in responsive tumours, the proportion of responsive
tumours is substantially limited in HNSCC. Appropriate patient
selection is the key factor in tumour immunotherapy; however,
previous studies have shown a discrepancy between immunother-
apy response and PD-L1 IHC expression. We expect that the
present subtype classification will be useful as a companion
diagnostic tool for OPC patients in clinical settings. The develop-
ment of convenient techniques, such as IHC or nanostring RNA
detection, for determining OPC subtypes should facilitate effective
immunotherapy in OPC patients. In the future, subtype-based
combination therapy trials, such as combination of other immune
checkpoint blockades (LAG3 or TIGIT with PD-1) in IR type, TGF-β
inhibition in MS type and anti-CD73 therapy in XB type will likely
broaden the scope of application of immunotherapy strategies in
OPC cancer patients.
In this study, we thoroughly studied OPC tumours using a
combination of RNA-seq, targeted sequencing and multiplex IHC
analysis. However, our study has limitations because of its
retrospective nature, and a limited sample size. The differential
response of OPC subtypes to anti-PD-1/PD-L1 therapy should be
interpreted with caution because only nine patients were
analysed. Further studies are warranted to validate our findings.
The proportion of tumour stage was also different among three
subtypes (Supplementary Table S2), and the clinical implication of
the difference needs to be investigated in another cohort.
In conclusion, our study firstly demonstrates distinct immune
microenvironments in subtypes of OPC tumours and their clinical
implications in patient prognosis and response to anti-PD-1/PD-L1
therapy. We suggest that the appropriate classification of tumour
subtypes is an essential step towards effective immunotherapy in
OPC patients. Our findings are expected to improve treatment
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Fig. 6 The molecular subtype predicts response to anti-PD-1/PD-L1 therapy in OPC patients. a The patient list and clinical characteristics of
nine recurrent or metastatic OPC patients receiving anti-PD-1/PD-L1 therapy (YOPD). *The best response was determined by RECIST 1.1
criteria. **Patient still undergoing anti-PD-1/PD-L1 therapy. b The t-SNE plot for nine YOPD tumours combined with 37 YOPC tumours. The
subtype of YOPD tumours was determined by distance from 37 YOPC tumours on the t-SNE plot. c Spider plot showing changes in target
lesion diameters on anti-PD-1/PD-L1 therapy in nine OPC tumours according to subtype. d Representative CT scan images of IR type and XB
type tumours on anti-PD-1/PD-L1 therapy.
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outcomes by enabling reliable molecular diagnosis and combina-
tion immunotherapy.
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